Multiple myeloma, a complex blood cancer rooted in the bone marrow, affects 160K people globally each year, with a mortality rate of 106K. According to DelveInsight, nearly 75K new cases were reported across seven major markets in 2023, a figure expected to climb in the coming years. Yet, amid these sobering statistics, a wave of progress is reshaping the multiple myeloma treatment landscape, offering new hope to patients facing this challenging disease.
Traditionally, the fight against multiple myeloma has leaned on chemotherapy and steroids—reliable, if broad, tools. But the story has shifted in recent years, with therapies like CAR-T cell therapy stepping in to ...
